Guselkumab Shows Superior Efficacy Over Ustekinumab for treatment of Psoriatic Arthritis: Study

Researchers Thilakarathne P and colleagues conducted an IPD analysis, pooling data from the DISCOVER-1, DISCOVER-2, PSUMMIT-1, and PSUMMIT-2 trials, encompassing a total of 44,115 participants. The analysis focused on evaluating joint and skin efficacy outcomes, including American College of Rheumatology 20% improvement (ACR20) and Psoriasis Area Severity Index 90% reduction (PASI 90) response rates.

Key Findings:

• Four MetS score trajectory patterns were identified: low-stable, moderate-low, moderate-high, and elevated-increasing.

• Compared to participants with a low-stable trajectory pattern, those with an elevated-increasing pattern had a higher risk of overall and site-specific cancers.

• Trajectories of MetS scores were associated with the occurrence of cancers, emphasizing the importance of long-term monitoring and evaluation of MetS.

The study highlights the significance of considering MetS score trajectory patterns in assessing cancer risk, particularly in individuals with elevated or increasing trajectories. Long-term monitoring of MetS may aid in early detection and intervention strategies for cancer prevention.

Reference:

Thilakarathne P, Schubert A, Peterson S, Noel W, Patel BP, Hassan F. Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from the DISCOVER and PSUMMIT Trials. Rheumatol Ther. 2024;11(2):457-474. doi:10.1007/s40744-024-00644-7